Nano Biotherapeutics Inc is developing a drug platform to treat acute and chronic inflammation and tissue injury in the heart and lungs using albumin nanoparticle mediated drug delivery. The nano drug platform is based on albumin, a natural protein, and the firm's nanoparticle can entrap small hydophobic drugs.The nanoparticel is loaded with an anti-inflammatory drug to target activated neutrophils, which accumulates at the site of injury. Then, the released drug suppresses inflammation.